trial

Add-on Methotrexate for the Treatment of Schizophrenia

NCTId NCT03369795
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Unknown
Enrollment 100 (estimated)
Sponsored by Sheba Medical Center
Primary completion 2020-01-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Unknown
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-12-15
Primary completion
2020-01-01
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Methotrexate

Sponsors

Sheba Medical CenterLead Sponsor

Sites

0 total

Linked catalysts

1
Add-on Methotrexate for the Treatment of Schizophrenia — primary completion2020-01-01

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE2
Primary Completion Date
2020-01-01
Status
UNKNOWN
relationships
The graph out of here
drug
Methotrexate
drug
lead_sponsor
Sheba Medical Center
company
indication
Schizophrenia
indication
Schizophrenia
indication